IGC Pharma, Inc. (IGC) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
IGC currently has 98.2M outstanding shares. with significant dilution risk as 357M authorized shares could dilute existing holders by 363.3%. The company has significantly diluted shareholders by 33.26% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
10-Q filing | 98.2M shares outstanding |
98M | 360M |
| Dec 03, 2025 |
S-3/A filing: This prospectus relates to the resale by the selling stockholders of up to 978,235 shares of common stock including (i) 588,235 shares of common stock and (ii) 390,000 shares of common stock underlying options to purchase common stock. |
83M | 370M |
| Aug 14, 2025 |
10-Q filing | 83.0M shares outstanding |
83M | 370M |
| Jul 18, 2025 |
S-3 filing: This S-3 filing relates to the resale by selling stockholders of up to 4,744,326 shares of common stock. |
77M | 380M |
| Jun 27, 2025 |
10-K filing | 76.5M shares outstanding |
77M | 370M |
| Feb 14, 2025 |
10-Q filing | 77.6M shares outstanding |
78M | 370M |
| Nov 12, 2024 |
10-Q filing | 76.0M shares outstanding |
76M | 370M |
| Aug 07, 2024 |
10-Q filing | 72.8M shares outstanding |
73M | 380M |
| Jun 24, 2024 |
10-K filing | 75.6M shares outstanding |
76M | 370M |
| Apr 18, 2024 |
S-3 filing: This S-3 filing relates to the resale by the selling stockholder of up to 8,823,529 shares of common stock. The closing price of the common stock on April 12, 2024, was $0.44 per share. |
64M | 390M |
| Feb 14, 2024 |
10-Q filing | 63.7M shares outstanding |
64M | 380M |
| Dec 29, 2023 |
S-3 filing: The filing is an S-3 registration for common stock, warrants, units, and rights that may be sold from time to time in one or more offerings up to a total dollar amount of $100,000,000. |
64M | 380M |
| Nov 09, 2023 |
10-Q filing | 63.7M shares outstanding |
64M | 43M |
| Sep 29, 2023 |
S-3 filing: This S-3 filing relates to the resale of up to 10,000,000 shares of common stock by selling stockholders. |
53M | 54M |
| Aug 10, 2023 |
10-Q filing | 53.1M shares outstanding |
53M | 44M |
| Jul 07, 2023 |
10-K filing | 52.6M shares outstanding |
53M | 44M |
| Feb 14, 2023 |
10-Q filing | 52.4M shares outstanding |
52M | 44M |
| Nov 01, 2022 |
10-Q filing | 52.1M shares outstanding |
52M | 45M |
| Sep 09, 2022 |
8-K filing: On September 9, 2022, India Globalization Capital held the Annual Meeting, where stockholders elected Ram Mukunda, Congressman James Moran, and Claudia Grimaldi to the Board of Directors and approved the grant of 3,000,000 shares of common stock to employees, advisors, directors, and consultants. |
52M | 45M |
| Aug 05, 2022 |
10-Q filing | 51.6M shares outstanding |
52M | 45M |
| Jun 23, 2022 |
10-K filing | 50.0M shares outstanding |
50M | 47M |
| Feb 10, 2022 |
10-Q filing | 49.6M shares outstanding |
50M | 47M |
| Oct 29, 2021 |
10-Q filing | 48.9M shares outstanding |
49M | 48M |
| Aug 11, 2021 |
10-Q filing | 47.9M shares outstanding |
48M | 49M |
| Jun 14, 2021 |
10-K filing | 48.3M shares outstanding |
48M | 49M |
| Feb 16, 2021 |
10-Q filing | 40.9M shares outstanding |
41M | 56M |
| Dec 23, 2020 |
S-3 filing: The filing is an S-3 registration statement for common stock, warrants, units, and rights that the company may sell from time to time in one or more offerings up to a total dollar amount of $100,000,000. |
41M | 56M |
| Nov 20, 2020 |
10-Q filing | 40.7M shares outstanding |
41M | 0 |
| Aug 19, 2020 |
10-Q filing | 40.2M shares outstanding |
40M | 0 |
| Jul 13, 2020 |
10-K filing | 39.5M shares outstanding |
39M | 0 |
| May 13, 2020 |
8-K filing: The Company acquired seven hundred fifty (750) shares of issued and outstanding common stock of Evolve (approximately 20% of Evolve) in exchange for $148,722.75 in cash and 100,514 shares of common stock of the Company. |
40M | 0 |
| Mar 16, 2020 |
8-K filing: On February 15, 2020, the Company signed a Share Subscription Agreement with Evolve, to acquire 750 shares of issued and outstanding common stock of Evolve (approximately 20% of Evolve) in exchange for $148,722.75 in cash at closing and 100,514 shares of common stock of the Company. ($0.15M proceeds) |
40M | 0 |
| Feb 10, 2020 |
10-Q filing | 39.6M shares outstanding |
40M | 0 |